Please login to the form below

Not currently logged in
Email:
Password:

Biovitrum

This page shows the latest Biovitrum news and features for those working in and with pharma, biotech and healthcare.

Sanofi and Sobi announce positive phase 3 trial results for severe haemophilia A

Sanofi and Sobi announce positive phase 3 trial results for severe haemophilia A

Sanofi and Swedish Orphan Biovitrum (Sobi) have announced positive results from a phase 3 trial, showing once-weekly efanesoctocog alfa provided ‘clinically meaningful’ bleed protection for patients with severe haemophilia A.

Latest news

More from news
Approximately 5 fully matching, plus 18 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions.

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum. Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 7 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...